Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase ⅠStudy of GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Treating Patients With Advanced Relapsed or Refractory Hematological Malignancies and Previously Treated Solid Tumors

NCT04944888 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT04944888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04944888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase ⅠStudy of GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Treating Patients With Advanced Relapsed or Refractory Hematological Malignancies and Previously Treated Solid Tumors
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2021
Completion date
November 30, 2023
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancy, solid tumor